International Journal of Alzheimer s Disease · 2011 · 92 citations · 35 references
Life SciencesBiochemistryPharmacologyEnzymologyNeurodegenerationSignal TransductionAlzheimer DiseaseAmyloid FormationEnzyme InhibitionNeurodegenerative DiseasesNeurodegenerative DisordersTau PathologyAlzheimer Disease Tau PathologyAmyloid Beta PathwaysAmyloid Beta-targeted TherapyGlycogen Synthase Kinase 3 RegulationGlycogen Synthase Kinase 3 SignalingTherapeutic Targeting Of Amyloid
Glycogen synthase kinase 3 (GSK-3), a proline/serine protein kinase ubiquitously expressed and involved in many cellular signaling pathways, plays a key role in the pathogenesis of Alzheimer's disease (AD) being probably the link between β-amyloid and tau pathology. A great effort has recently been done in the discovery and development of different new molecules, of synthetic and natural origin, able to inhibit this enzyme, and several kinetics mechanisms of binding have been described. The small molecule called tideglusib belonging to the thiadiazolidindione family is currently on phase IIb clinical trials for AD. The potential risks and benefits of this new kind of disease modifying drugs for the future therapy of AD are discussed in this paper.
35
Ana Martı́nez, Mercedes Alonso, Ana Castro et al. · Journal of Medicinal Chemistry · 2002 · 447 citations · Full text
Karelle Leroy, Zehra Yilmaz, Jean‐Pierre Brion · Neuropathology and Applied Neurobiology · 2007 · 394 citations · Full text